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ease; certain groups are spared, including those in the oculo-
motor nucleus controlling eye movement. The reasons for
this diﬀerential vulnerability remain unknown. Here we have
identiﬁed a protein signature for resistant oculomotor motor
neurons and vulnerable hypoglossal and spinal motor neu-
rons in mouse and man and in health and ALS with the aim
of understanding motor neuron resistance. Several proteins
with implications for motor neuron resistance, including
GABAA receptor a1, guanylate cyclase soluble subunit
alpha-3 and parvalbuminwere persistently expressed in ocu-
lomotor neurons in man and mouse. Vulnerable motor neu-
rons displayed higher protein levels of dynein, peripherin
andGABAA receptora2, which play roles in retrograde trans-
port and excitability, respectively. These were dynamically
regulatedduringdiseaseand thuscouldplacemotorneurons
at an increased risk. From our analysis is it evident that ocu-
lomotormotorneuronshaveadistinct proteinsignaturecom-
pared to vulnerable motor neurons in brain stem and spinal
cord, which could in part explain their resistance to degen-
eration in ALS. Our comparison of human and mouse shows
the relative conservation of signals across species and infers
that transgenic SOD1G93A mice could be used to predict
mechanisms of neuronal vulnerability in man.  2015 The
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal disease
characterized by a progressive loss of somatic motor
neurons in the spinal cord and brain stem. However,
certain groups of somatic motor neurons, including
those in the oculomotor nucleus (CNIII), which control
eye movements, and those in Onuf’s nucleus, that
control pelvic muscles, are generally spared (Gizzi
et al., 1992; Kubota et al., 2000; Nimchinsky et al.,
2000; Haenggeli and Kato, 2002; Tjust et al., 2012).
The reasons for this diﬀerential vulnerability among motor
neurons remain unknown.
ALS can be inherited (familial, fALS, 10%) due to
mutations identiﬁed in a number of genes, the two most
common of which are superoxide dismutase 1 (SOD1)
and C9ORF72 (chromosome 9 open reading frame 72)
(Al-Chalabi et al., 2012), but the majority of ALS cases
appear sporadic (sALS, 90%). The pathology and pat-
tern of selective motor neuron vulnerability is similar in
fALS and sALS (Shaw et al., 1997). This indicates that dif-
ferential vulnerability is independent of the cause of dis-
ease. Therefore elucidation of the mechanisms of
selective vulnerability in mouse models of fALS could be
applicable also to sALS. Importantly, in vivo and in vitro
models of fALS indicate that factors intrinsic to motor neu-
rons are crucial for initiation of degeneration (Boillee et al.,
2006; Jaarsma et al., 2008; Huang et al., 2012; Kiskinis
et al., 2014), while astrocytes and microglia drive disease
progression (Boillee et al., 2006; Yamanaka et al., 2008;
Das and Svendsen, 2014). It therefore seems that diﬀer-
ential expression of factors intrinsic to motor neurons ren-
der these cells more or less vulnerable to toxic events
(Saxena et al., 2009; Hedlund et al., 2010; Kaplan et al.,
2014). Thus, identiﬁcation of cell intrinsic mechanisms
of protection and vulnerability may lead to therapies pre-
venting the progressive loss of motor neurons. Toward
this goal, we previously analyzed the global gene expres-
sion proﬁles of vulnerable spinal and hypoglossal motor
neurons and spared oculomotor and trochlear neuron
groups in the normal rat and identiﬁed multiple intrinsic
factors that may underlie their diﬀerential vulnerability
(Hedlund et al., 2010).
To further our understanding of motor neuron
vulnerability and resistance, we selected six genes thatons.org/licenses/by-nc-sa/4.0/).
Table 1. Candidate genes selected for across species analysis in health and ALS based on diﬀerential mRNA expression
Gene name Known biological functions Motor neurons with highest
mRNA level*
Control rat
Gucy1a3 Main receptor for nitric oxide (Zabel et al., 1998), potentially implicated in modulating Fas ligand
activation (Hedlund et al., 2010)
CNIII
Parvalbumin Calcium-binding protein with motor neuron protective eﬀects (Van Den Bosch et al., 2002;
Dekkers et al., 2004)
CNIII
Gabra1 Inhibitory synaptic transmission, neuronal excitability (Lorenzo et al., 2006; Brockington et al.,
2013)
CNIII
Gabra2 Inhibitory synaptic transmission, neuronal excitability (Lorenzo et al., 2006; Brockington et al.,
2013)
SC
Peripherin Intermediate neuroﬁlament, over-expression of which causes ALS-like MN loss (Beaulieu et al.,
1999)
CNXII and SC
Dynein Retrograde transport protein, mutations in which are linked to motor neuron degeneration
(LaMonte et al., 2002; Hafezparast et al., 2003)
CNXII and SC
CNIII = oculomotor nucleus, CNXII = hypoglossal nucleus, SC = spinal cord.
* Based on our previously published gene array study (Hedlund et al., 2010).
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susceptible motor neurons in the healthy rodent
(Hedlund et al., 2010), and analyzed the corresponding
protein levels in health and ALS, in man and mouse.
Speciﬁcally, the proteins analyzed in this study were
guanylate cyclase soluble subunit alpha-3 (Gucy1a3),
parvalbumin, GABAA receptor a1 (Gabra1), GABAA
receptor a2 (Gabra2), peripherin and dynein, which all
have previous implications for motor neuron disease
(summarized in Table 1). Our initial analysis was per-
formed in early symptomatic mutant SOD1G93A fALS mice
and wild-type litter-mates. In order to elucidate if genes
showed similar expression patterns and regulation in
human disease and thus could be inferred to play a role
in protection and vulnerability we subsequently analyzed
post mortem tissues from non-demented (ND) controls
and sporadic ALS patients. Our analysis showed that
resistant oculomotor motor neurons have a distinct pro-
tein signature, which is relatively conserved between
man and mouse. This unique proﬁle could in part explain
their preservation in ALS when other motor neurons
degenerate.EXPERIMENTAL PROCEDURES
Ethics statement
All thework involving animal or humansubjects/tissueshas
been carried out in accordance with the Code of Ethics of
the World Medical Association (Declaration of Helsinki)
and with national legislation as well as our institutional
guidelines. Ethical approval for the use of the human
samples analyzed in this publication was obtained by
Dr. Hedlund from the regional ethical review board in
Stockholm, Sweden (Regionala Etikpro¨vningsna¨mnden,
Stockholm, EPN, http://www.epn.se/sv/stockholm/
om-naemnden/), approval number 2012/111-31/1. All
human tissues were obtained from the Netherlands Brain
Bank (NBB, www.brainbank.nl) or the National Disease
Research Interchange (NDRI, www.ndriresource.org)
with the written informed consent from the donors or the
next of kin. All procedures involving animals wereapproved by the Swedish animal ethics review board
(Stockholms Norra Djurfo¨rso¨ksetiska na¨mnd, http://www.
jordbruksverket.se/amnesomraden/djur/olikaslagsdjur/
forsoksdjur/etiskprovning.html) with ethical approval
numbers N352/11, N264/12 and N82/13 (Hedlund).Mouse tissue processing
Analysis was performed on tissues from 112-day-old
(P112) early-symptomatic SOD1G93A fALS mice, which
display hindlimb tremors and partial denervation of motor
end-plates (Fischer et al., 2004; Schaefer et al., 2005).
P112 SOD1G93A mice on a C57Bl/6J background
(Gurney, 1994) and age-matched wild-type litter-mates
from the same colony, were anesthetized with avertin (tri-
bromoethanol, Sigma) and perfused intracardially with
phosphate-buﬀered saline (PBS) followed by 4%
paraformaldehyde (PFA). Brains and spinal cords were
dissected and postﬁxed (for 3 and 1 h respectively). All tis-
sues were cryoprotected in sucrose and sectioned
(30 lm).Immunoﬂuorescence analysis of mouse tissues
Tissues were blocked in 10% donkey serum (Jackson
Laboratories, West Grove, PA, USA) and 0.1% Triton-
X100 (Sigma-Aldrich AB, Stockholm, Sweden) in PBS
for 1 h prior to incubation with primary antibodies
(Table 2) overnight at 4 C. This was followed by
incubation with Alexaﬂuor secondary antibodies (1:500)
for 1 h, counter staining with either Hoechst 33342 or
Neurotrace 435 (1:200, Invitrogen) and coverslipping for
confocal analysis (Zeiss lsm700). Negative controls
were performed for all stainings by omitting either
primary or secondary antibodies.Human tissue processing
Human brain and spinal cord tissues from ALS patients
and ND controls were retrieved from the Netherlands
Brain Bank (NBB, http://www.brainbank.nl) and the
National Disease Research Interchange (NDRI, http://
Table 2. Antibodies used for immunoﬂuorescence and
immunohistochemistry
Target Source Host
species
Concentration
in mouse
tissue
Concentration
in human
tissue
ChAT Millipore Goat 1:300 1:50
ChAT Millipore Rabbit 1:200 –
Dynein Abcam Rabbit 1:100 1:100
Gabra1 Millipore Rabbit 1:200 1:100
Gabra2 Abcam Rabbit 1:500 1:100
Gabra2 Santa
Cruz
Goat – 1:50
Gucy1a3 Abgent Rabbit – 1:60
Gucy1a3 Abcam Rabbit 1:1000
Parvalbumin Millipore Rabbit 1:500 1:200
Peripherin Millipore Rabbit 1:100 –
Peripherin Millipore Mouse – 1:100
Table 3. Characteristics of non-demented and ALS clinical cases used
for immunohistochemical analysis
Case
number
Sex Age at
death
Neurological
diagnosis
Postmortem
delay time
(h:min)
Source
1 F 58 Non-
demented
14:10 NDRI
2 M 70 Non-
demented
4:50 NDRI
3 F 71 Non-
demented
7:10 NBB
4 M 71 Non-
demented
7:40 NBB
5 F 87 Non-
demented
5:00 NBB
6 F 49 ALS 3:45 NBB
7 M 65 ALS 10:30 NDRI
8 M 71 ALS 6:45 NBB
9 M 74 ALS 7:20 NDRI
NBB – Netherlands Brain Bank (http://www.brainbank.nl).
NDRI – National Disease Research Interchange (http://www.ndriresource.org/).
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31/1, Hedlund). The characteristics of ND and ALS
clinical cases used for immunohistochemical analysis
are listed in Table 3. Tissues from NBB were received
embedded in paraﬃn and were sectioned (10 lm) on a
sliding microtome. Tissues from NDRI were ﬁxed in
PFA, sequentially placed through sucrose gradients
(2%, 10%, 20% and 30%) for cryoprotection and
sectioned (40 lm) on a freezing microtome. NBB tissue
was deparaﬃnized and all tissue was subjected to
antigen retrieval (0.01 M citric acid buﬀer, pH 6.0 for
20 min at 95 C) and blocking of endogenous
peroxidases (3% H2O2 in 50% methanol in PBS) prior to
staining.
Immunohistochemistry of human tissues
As the majority of the human tissues were paraﬃn
embedded, resulting in high background levels when
subjected to immunoﬂuorescent staining, we chose to
perform the analysis of human tissues with aperoxidase-based system. Tissue was blocked and
incubated with primary antibodies (Table 2) as described
above prior to incubation with biotinylated secondary
antibodies (1:300; Jackson Laboratories) for 3 h,
followed by incubation in streptavidin–biotin complex
(Vectastain ABC kit Elite, Vector Laboratories,
Burlingame, CA, USA) for 1 h and visualized by
incubation in 3,30-diaminobenzidine solution (DAB,
Vector Laboratories). Nuclei were counterstained using
Myers hematoxylin (Histolab) and tissue was dehydrated
by sequential steps in increasing ethanol concentration
and coverslipped using Mountex (Histolab). Brightﬁeld
images were captured using a Zeiss Axio Imager M1
Upright microscope. Negative controls were performed
for all stainings by omitting either primary or secondary
antibodies.
Intensity measurements
In order to assess signal intensity of candidate proteins in
brain stem and spinal cord motor neurons, micrographs
were taken of our regions of interest; CNIII, trochlear
nucleus (CNIV), hypoglossal nucleus (CNXII) and
ventral horn of the spinal cord. Acquisition settings were
optimized for each candidate protein to avoid any
saturation of signal, which could aﬀect intensity
calculations (Waters, 2009). Care was taken to consis-
tently image the motor neuron population of interest at
the same point on the rostral-caudal axis using morpho-
logical landmarks from atlases of rodent and human
brainstem anatomy. Signal intensity of candidate proteins
in motor neurons in the brain stem and spinal cord was
measured by outlining individual motor neuron somas
on micrographs and calculating average pixel intensity
using ImageJ software (http://rsb.info.nih.gov/ij/). To aid
mouse tissue analysis, sections were counter stained with
Nissl (Neurotrace 435) and antibodies against choline
acetyltransferase (ChAT), allowing us to easily identify
motor neurons. In order to avoid bias against motor neu-
rons with low levels of candidate protein expression all
motor neurons (identiﬁed by ChAT staining) within the
focal plane of a confocal micrograph (identiﬁed by a clear
nucleus within the soma, stained with Nissl) were included
in the analysis. In order to exclude interneurons (which
also express ChAT) only cell somas with an area
P200 lm2 were included. To aid human tissue analysis,
sections were initially stained with Nissl to identify CNIII,
CNXII and ventral horn of the spinal cord. Sections were
subsequently stained with antibodies against ChAT,
allowing us to easily visualize motor neurons, and adja-
cent sections were stained and quantiﬁed for intensity
levels of candidate proteins. As with rodent tissues, all
motor neurons within the focal plane of a micrograph were
included in the analysis. In order to exclude interneurons
from our analysis of human material, only cell somas with
an area P300 lm2 were included.
To correct for background in images, three
background intensity readings were taken per image.
These readings were subsequently averaged and
subtracted from the signal intensity within motor
neurons of the same area to give an accurate reading of
the candidate protein staining intensity. The signal
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normalized to a value of one. Signal intensity of
candidate proteins within CNXII and spinal cord was
then compared to this value to assess if the intensity
was higher or lower than that seen in CNIII. The
scientists performing the intensity measurements and
quantiﬁcation of signal intensity for this study were
blinded to the genotype of the animals and the
diagnosis of the patients.
Statistical analysis
All statistical analyses were performed with GraphPad
Prism software. A one-way analysis of variance
(ANOVA) was used to compare the mean intensity of
candidate proteins in CNIII, CNXII and spinal cord. A
two-way ANOVA was used when several variables were
taken into account (intensity across anatomical regions
and disease status), followed by Tukey’s post hoc
analysis of mean diﬀerences between groups. Individual
statistical tests are detailed in the ﬁgure legends. In the
ﬁgures, the signiﬁcance of the statistical analysis is
marked by ⁄, where ⁄P< 0.05, ⁄⁄P< 0.01,
⁄⁄⁄P< 0.001 and ⁄⁄⁄⁄P< 0.0001. The F value used for
2-way ANOVAs refers to the eﬀect of genotype (wild-
type versus SOD1G93A). The number of animals used
for each experiment is listed in the ﬁgure legends and
the number of motor neurons measured for each
candidate protein is listed in Table 4. All experiments for
Figs. 1–7 were performed in triplicate or quadruplicate.
All results are expressed as mean ± SEM.Table 4. Number of motor neurons used to quantify signal intensity in
immunostained tissues
Protein Tissue origin Motor neuron counts
CNIII CNXII cSC
Gucy1a3 Wild-type mouse 134 145 137
SOD1G93A mouse 153 154 67
ND Control patient 104 96 64
ALS patient 97 104 64
Parvalbumin Wild-type mouse 97 51 57
SOD1G93A mouse 90 47 60
ND Control patient 100 80 78
ALS patient 70 63 50
Peripherin Wild-type mouse 80 83 60
SOD1G93A mouse 108 116 88
ND Control patient 92 51 59
ALS patient 42 52 34
Dynein Wild-type mouse 91 124 77
SOD1G93A mouse 115 75 65
ND Control patient 58 64 37
ALS patient 61 54 45
Gabra1 Wild-type mouse 112 64 136
SOD1G93A mouse 48 24 79
ND Control patient 90 68 63
ALS patient 92 74 82
Gabra2 Wild-type mouse 65 51 138
SOD1G93A mouse 43 23 102
ND Control patient 102 103 126
ALS patient 125 204 146RESULTS
Our previous work in the normal rat identiﬁed diﬀerential
gene expression between resistant and vulnerable
motor neurons, which may in part underlie their
diﬀerential susceptibility to disease (Hedlund et al.,
2010). In the present work we aimed to understand the
regulation of the resulting proteins in health and ALS
and across species, utilizing symptomatic fALS mice,
end-stage ALS patient tissues and control patient tissues.
We selected six genes that show preferential expression
either in resistant oculomotor or in vulnerable hypoglossal
and spinal motor neurons in the normal rat (Hedlund et al.,
2010), including Gucy1a3, parvalbumin, Gabra1, Gabra2,
peripherin and dynein. We analyzed the resulting protein
levels within resistant oculomotor and vulnerable
hypoglossal and spinal motor neuron somas. A summary
of the expression data presented below in the results sec-
tion and the known biological functions of the proteins can
be found in Tables 1 and 5, respectively.Gucy1a3 and parvalbumin are regulated in ALS in
human and mouse
Our analysis of protein expression within resistant and
vulnerable motor neuron somas in health and ALS,
using immunoﬂuorescent staining and
immunohistochemistry, was initiated by measuring the
levels of Gucy1a3 and parvalbumin. Gucy1a3, which
functions as the main receptor for nitric oxide (Zabel
et al., 1998) and thus could be implicated in modulating
Fas ligand activation (Hedlund et al., 2010), showed the
highest relative ﬂuorescent intensity in oculomotor motor
neurons in wild-type mice (Fig. 1A–D, F(2,
413) = 26.72, P< 0.0001). In SOD1G93A mice Gucy1a3
was instead present at comparable levels in all motor neu-
ron nuclei measured (Fig. 1E–H, F(2, 371) = 1.179,
P= 0.3086). There was a signiﬁcant down-regulation of
Gucy1a3 in all motor neuron groups in SOD1G93A mice
compared to wild-type littermates. Speciﬁcally, ﬂuores-
cence intensity levels decreased from 1.07 ± 0.04 to
0.63 ± 0.02 in oculomotor neurons, from 0.82 ± 0.03 to
0.65 ± 0.02 in hypoglossal and from 0.82 ± 0.02 to
0.54 ± 0.03 in spinal motor neurons (Fig. 1Q, F(1,
784) = 166.8, P< 0.0001). The level of the
calcium-binding protein parvalbumin was the highest in
oculomotor motor neurons (1.04 ± 0.06 relative intensity)
in control mice. The parvalbumin levels were also high in
spinal motor neurons (0.73 ± 0.03), while almost absent
in hypoglossal motor neurons (0.17 ± 0.03), consistent
with previous studies (Laslo et al., 2000) (Fig. 1I–L, F(2,
202) = 69.89 , P< 0.0001). In the SOD1G93A mice, the
level of parvalbumin was now instead the highest in spinal
motor neurons (1.37 ± 0.08) (Fig. 1M–P, F(2,
194) = 64.53 , P< 0.0001), due to a signiﬁcant decrease
in relative intensity from 1.04 ± 0.06 to 0.63 ± 0.04 in
oculomotor neurons (Fig. 1Q, F(1, 396) = 9.883,
P< 0.0001). To control for unspeciﬁc antibody labeling
we omitted either the primary antibody or the secondary
antibody from the staining protocol. This analysis con-
ﬁrmed that all stainings conducted for this study were spe-
ciﬁc. Representative images of the negative control
Fig. 1. Gucy1a3 and parvalbumin show diﬀerential motor neuron expression and are regulated during motor neuron disease in SOD1G93A fALS
mice. Immunoﬂuorescence was used to analyze protein expression patterns and levels in wild-type and SOD1G93A mice at P112. Gucy1a3 (A–D)
was preferential to oculomotor motor neurons (P< 0.0001, n= 4, ANOVA) in wild-type mice. In symptomatic SOD1G93A fALS mice, Gucy1a3
protein levels were comparable in all motor neuron pools measured (E–H, P= 0.3086, n= 4, ANOVA). All motor neuron groups showed a
signiﬁcant down-regulation of Gucy1a3 with disease (Q, P< 0.0001, n= 4+ 4, 2-way ANOVA). Parvalbumin levels were the highest in
oculomotor neurons in control mice, followed by spinal motor neurons (I–L; P< 0.0001, n= 4, ANOVA). However, in the SOD1G93A mice
parvalbumin levels were instead the highest in spinal motor neurons, followed by oculomotor neurons (M–P; P< 0.0001, n= 4, ANOVA), due to a
signiﬁcant drop in parvalbumin intensity level in oculomotor motor neurons compared to wild-type (Q, P< 0.0001, n= 4+ 4, 2-way ANOVA).
Negative control stainings, to control for unspeciﬁc labeling by antibodies were done by omitting either the primary or secondary antibodies. Staining
against parvalbumin using primary antibody only (R) or secondary antibody only (S) did not result in any unspeciﬁc staining. Scale bar = 50 lm in
O, applicable to A–O.
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Table 5. Summary of candidate protein analysis across species in health and ALS
Protein Motor neurons with highest protein level Changes in protein levels in
disease
Relevant
ﬁgures
Control
mouse
Control human
patient
End stage ALS human
patient
Symptomatic fALS mouse
Gucy1a3 CNIII CNIII All motor neurons Yes Figs. 1 and 3
Parvalbumin CNIII SC CNIII Yes Figs. 1–3
Gabra1 CNIII CNIII CNIII Yes Figs. 4 and 5
Gabra2 SC SC SC No Figs. 4 and 5
Peripherin SC CNXII and SC CNXII and SC Yes Figs. 6 and 7
Dynein SC CNXII and SC All motor neurons Yes Figs. 6 and 7
CNIII = oculomotor nucleus, CNXII = hypoglossal nucleus, SC = spinal cord.
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including CNIII, using either primary antibody only
(Fig. 1R) or secondary antibody only (Fig. 1S). Important-
ly, parvalbumin levels diﬀered greatly among motor neu-
rons within CNIII (Fig. 2A–C, J, standard deviation
(SD) = 0.54) and CNIV in control animals (Fig. 2D–F)
and in symptomatic SOD1G93A mice (Fig. 2K,
SD = 0.56). Thus, while most motor neurons in these
resistant nuclei expressed parvalbumin, some appeared
almost devoid of this protein. Spinal cord motor neurons
showed relatively homogenous parvalbumin levels in
wild-type animals (Fig. 2G–J, SD = 0.24). However, in
disease expression levels varied greatly between indi-
vidual spinal motor neurons (Fig. 2K, SD= 0.63) with a
2.6-fold increase in standard deviation compared to
wild-type when considering relative intensity levels
between cells.
To investigate if these two proteins could potentially
play a role in motor neuron resistance and vulnerability
in man we performed an analysis in postmortem brain
and spinal cord tissues from ND controls and ALS
patients. Gucy1a3 protein levels were the highest in
oculomotor neurons (1 ± 0.03 relative intensity),
followed by hypoglossal motor neurons (0.89 ± 0.04)
and lowest in spinal motor neurons (0.74 ± 0.05) in
control tissues (Fig. 3A–E, F(2, 261) = 12.73,
P< 0.0001). Thus, the higher expression in oculomotor
neurons appears conserved between mouse and man.
In end-stage ALS patients, Gucy1a3 was still present in
oculomotor neurons, but the levels were not signiﬁcantly
diﬀerent from motor neurons in CNXII and the spinal
cord (Fig. 3F–I, F(2, 262) = 3,241, P= 0.0407). This is
similar to the pattern seen in the symptomatic
SOD1G93A mouse.
Parvalbumin levels were the highest in spinal motor
neurons (1.19 ± 0.05 relative intensity) in control patient
tissues, followed by oculomotor neurons (1.00 ± 0.03).
The level of parvalbumin in hypoglossal motor neurons
(0.64 ± 0.03) was signiﬁcantly lower compared to both
oculomotor and spinal motor neurons (Fig. 3J–M, F(2,
255) = 52.51, P< 0.0001), consistent with the mouse.
In ALS patients, parvalbumin levels were signiﬁcantly
higher in oculomotor motor neurons (1.00 ± 0.06)
compared to spinal (0.72 ± 0.06) and hypoglossal
(0.68 ± 0.05) motor neurons (Fig. 3N–Q, F(2,
180) = 11.27, P< 0.0001).Gabra1 and Gabra2 show opposing motor neuron
expression patterns
It has been proposed that diﬀerent levels of excitability
can underlie some of the diﬀerences in motor neuron
vulnerability in ALS. The SOD1G93A mice show motor
neuron hyperexcitability early in life (van Zundert et al.,
2008) and insuﬃcient synaptic inhibition (Lorenzo
et al., 2006; Chang and Martin, 2011), which can be
modulated through glycine and GABAA receptor expres-
sion. We therefore investigated the expression pattern of
Gabra1 and (Gabra2) in mouse and man and in health
and ALS. Our analysis showed that Gabra1 was prefer-
entially expressed in oculomotor motor neurons in wild-
type (Fig. 4A–D, F(2, 309) = 97.18, P< 0.0001) and
SOD1G93A mice (Fig. 4E–H, F(2, 148) = 62.86,
P< 0.0001).
In the ALS mice, Gabra1 protein levels were
increased compared to wild-type, from a relative
intensity of 1.00 ± 0.03 to 1.47 ± 0.07 in oculomotor
motor neurons and from 0.64 ± 0.02 to 0.90 ± 0.03 in
spinal motor neurons (Fig. 4Q, F(1, 469) = 55.69,
P< 0.0001). Gabra2 showed the opposite pattern to
Gabra1, with preferential localization in spinal motor
neurons (1.74 ± 0.07 relative intensity) and lower levels
in hypoglossal (1.11 ± 0.09) and oculomotor
(1.00 ± 0.07) motor neurons in wild-type mice (Fig. 4I–L,
F(2, 251) = 40.75, P< 0.0001). Gabra2 was also
present at the highest level in spinal motor neurons
(1.92 ± 0.04) in SOD1G93A mice (Fig. 4M–P,
F(2, 165) = 89.46, P< 0.0001), at levels comparable to
wild-type (Fig. 4Q, F(1, 415) = 2.141, P= 0.1442).
Analysis of the signal intensity of Gabra1 staining in
human tissues showed that Gabra1 was preferential to
oculomotor motor neurons (1.00 ± 0.02 relative
intensity) compared to hypoglossal (0.66 ± 0.05) and
spinal (0.60 ± 0.06) in control patients (Fig. 5A–D, F(2,
218) = 24.14, P< 0.0001). The relatively high level of
Gabra1 in oculomotor neurons was maintained in ALS
patient tissues (Fig. 5E–H, F(2, 245) = 32.74,
P< 0.0001). These data are consistent with our
ﬁndings in mouse. Gabra2 showed predominant
expression in spinal motor neurons in control patients
(Fig. 5I–L, F(2, 328) = 16.29, P< 0.0001) and ALS
patients (Fig. 5M–P, F(2, 472) = 8.361, P= 0.0003).
Collectively, our data showed that GABAA receptor
Fig. 2. Levels of parvalbumin diﬀer greatly between individual motor neurons within an anatomical motor nucleus. Confocal analysis showed that
parvalbumin was present at diﬀerent levels in ChAT+ motor neurons within the oculomotor nucleus (A–C) and the trochlear nucleus (D–F) in wild-
type mice (J, standard deviation (SD) = 0.54, n= 97 motor neurons) and in SOD1G93A mice (K, SD= 0.56, n= 90 motor neurons). Parvalbumin
levels were relatively uniform in spinal motor neurons in wild-type mice (G–J, SD= 0.24, n= 57 motor neurons), while the intensity varied greatly in
SOD1G93A mice (K, SD= 0.63, n= 60 motor neurons). Arrows indicate ChAT+ motor neurons that appear to be devoid of parvalbumin, while
asterisks exemplify motor neurons that have high levels of parvalbumin. Scale bar = 100 lm in I, applicable to A–I.
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Fig. 3. Gucy1a3 and parvalbumin expression in non-demented control and end-stage ALS patient tissues. Motor neurons in the resistant
oculomotor nucleus and the vulnerable hypoglossal nucleus and ventral horn of spinal cord (shown in schematic A) in non-demented and ALS
patient tissues were analyzed for expression levels of proteins with predominant expression in oculomotor motor neurons in mouse. Gucy1a3
showed predominant localization to oculomotor motor neurons in control patients (B–E, P< 0.0001, n= 4, ANOVA), while in ALS patients the level
of Gucy1a3 was similar in all motor neuron groups (F-I, P= 0.0407, n= 4, ANOVA). Parvalbumin was preferentially expressed in oculomotor and
spinal motor neurons compared to hypoglossal motor neurons in control, with the highest level in spinal motor neurons (J–M, P< 0.0001, n= 4,
ANOVA). In end-stage ALS patient tissue the level was the highest in oculomotor motor neurons (N–Q, P< 0.0001, n= 4, ANOVA). Scale
bar = 20 lm in P, applies to B–P.
L. Comley et al. / Neuroscience 291 (2015) 216–229 223distribution diﬀered between resistant and vulnerable
motor neurons in control mice and control patients.
These diﬀerences were maintained after the onset of
disease in SOD1G93A mice and in end-stage ALS patients.Peripherin and dynein are preferential to vulnerable
motor neurons in human and mouse and are
regulated in disease
Finally, we examined the dynamics of peripherin and
dynein protein levels in health and ALS. Peripherin,
which is an intermediate neuroﬁlament, was investigateddue to its previously shown associations with ALS (He
and Hays, 2004; Leung et al., 2004; Xiao et al., 2008)
and its preferential expression in vulnerable spinal motor
neurons in the normal rat (Hedlund et al., 2010). Quantiﬁ-
cation of ﬂuorescent intensity within motor neuron somas
showed that peripherin was predominantly expressed in
spinal motor neurons in wild-type (Fig. 6A–D, F(2,
220) = 32.71 P< 0.0001) and SOD1G93A mice
(Fig. 6E–H, F(2, 333) = 103.9 P< 0.0001). The relative
level of peripherin increased speciﬁcally in spinal motor
neurons from 1.18 ± 0.06 to 1.41 ± 0.06 in the
SOD1G93A mice, while it decreased in oculomotor (from
Fig. 4. Gabra1 and Gabra2 show opposing expression in resistant and vulnerable motor neurons in mouse. Immunoﬂuorescent analysis and
quantiﬁcation of relative intensity levels within motor neurons in wild-type mice showed that Gabra1 was preferentially expressed in oculomotor
motor neurons. Hypoglossal motor neurons showed the lowest Gabra 1 protein level (A-D, P< 0.0001, n= 5, ANOVA). In the SOD1G93A fALS
mice, Gabra1 continued to be preferentially expressed in oculomotor motor neurons (E–H, P< 0.0001, n= 3, ANOVA). The levels of Gabra1
remained relatively high in spinal motor neurons than in hypoglossal motor neurons in the SOD1G93A mice (H, P< 0.0001, n= 3, ANOVA).
Furthermore, there was a relative increase in expression in oculomotor and spinal motor neurons in ALS mice compared to wild-type mice (Q,
P< 0.0001, n= 5+ 3, 2-way ANOVA). Gabra2 was preferential to spinal motor neurons in wild-type mice (I–L, P< 0.0001, n= 4, ANOVA).
Gabra2 was present at the highest level in spinal motor neurons also in SOD1G93A mice. Furthermore, in the ALS mice, Gabra2 showed a relatively
high expression in oculomotor motor neurons than in hypoglossal motor neurons (P, P< 0.0001, n= 3, ANOVA). Disease did not induce
signiﬁcant changes in Gabra2 levels for the motor neuron groups analyzed (Q, P= 0.1442, n= 4+ 3, 2-way ANOVA). Scale bar = 50 lm in O,
applicable to A–O.
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Fig. 5. Gabra1 and Gabra2 show distinct motor neuron expression patterns in control and ALS patient tissues. Quantiﬁcation of immunohisto-
chemical signal intensity revealed that Gabra1 was preferentially expressed in oculomotor motor neurons in control patient tissues (A–D,
P< 0.0001, n= 3, ANOVA) and in end-stage ALS patient tissues (E–H, P< 0.0001, n= 3, ANOVA). Gabra2 was present at the highest level in
spinal motor neurons in non-demented patient control tissue (I–L, P< 0.0001, n= 3, ANOVA). In end-stage ALS patient tissue, Gabra2 still
remained the highest in spinal motor neurons. However, the diﬀerences between spinal motor neurons and the other motor neuron groups was
reduced (M–P, P= 0.0003, n= 3, ANOVA). Scale bar = 20 lm in O, applies to A–O.
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rons (from 0.97 ± 0.04 to 0.72 ± 0.04) with disease
(Fig. 6Q, F(1, 529) = 12.51, P= 0.0004).
The motor protein dynein is important for retrograde
transport, which is disrupted in ALS (Tanaka et al., 2012)
thereby making its regulation of interest. Dynein levels
were the highest in spinal motor neurons (2.43 ± 0.10
relative intensity), but were also signiﬁcantly higher in
hypoglossal (1.25 ± 0.06) than oculomotor (1.00 ± 0.05)
motor neurons in wild-type (Fig. 6I–L, F(2, 289) = 116.7,
P< 0.0001). SOD1G93A mice showed the same pattern
of relative protein levels (Fig. 6M–P, F(2, 252) = 68.57,
P< 0.0001), but the levels were signiﬁcantly decreased
in all motor neuron nuclei compared to wild-type mice
(Fig. 6Q, F(1, 541) = 423.1, P< 0.0001).
Analysis of human tissues showed that peripherin was
preferentially present in hypoglossal (1.72 ± 0.08) and
spinal motor neurons (1.59 ± 0.09) compared to
oculomotor motor neurons (1.00 ± 0.04) in control
patients (Fig. 7A–D, F(2, 200) = 39.84, P< 0.0001).This pattern was maintained in ALS patients (Fig. 7E–H,
F(2, 125) = 17.24, P< 0.0001). The higher level of
peripherin within spinal motor neurons than oculomotor
motor neurons appears consistent between man and
mouse, while the relatively high levels in hypoglossal
motor neurons appears speciﬁc to man. Dynein was
also preferential to hypoglossal (1.25 ± 0.06) and spinal
(1.38 ± 0.07) motor neurons compared to oculomotor
motor neurons (1.00± 0.05) in control patients (Fig. 7I–L,
F(2, 127) = 11.11, P< 0.0001), similar to mouse. In
end-stage ALS patients, dynein expression was
comparable in all motor neuron groups (Fig. 7M–P, F(2,
157) = 0.3510, P= 0.7046), through an apparent
decrease of protein levels (Fig. 7I–K versus M–O),
similarly to symptomatic fALS mice. Collectively, our
data show that dynein and peripherin are present at
higher levels in vulnerable than resistant motor neurons
in both man and mouse. It is also clear that there is
modulation of these proteins in disease, which would
result in dysregulation of retrograde transport.
Fig. 6. Peripherin and dynein are preferentially expressed in vulnerable motor neurons in wild-type and SOD1G93A fALS mice. Peripherin protein
levels were signiﬁcantly higher in motor neurons of the spinal cord than those in the oculomotor and hypoglossal nucleus of wild-type mice (A–D,
P< 0.0001, n= 3, ANOVA) and SOD1G93A mice (E–H, P< 0001, n= 4, ANOVA. Peripherin was speciﬁcally increased in spinal motor neurons in
the ALS mice, while the levels decreased in oculomotor and hypoglossal motor neurons with disease (Q, P= 0.0004, n= 3+ 4, 2-way ANOVA).
Dynein levels were the highest in spinal motor neurons followed by hypoglossal motor neurons in both control mice (I–L, P< 0.0001, n= 4,
ANOVA) and symptomatic ALS mice (M–P, P< 0.0001, n= 4, ANOVA). Dynein was decreased in all motor neuron nuclei in the SOD1G93A mice
compared to wild-type mice (Q, P< 0.0001, n= 4+ 4, 2-way ANOVA). Scale bar = 50 lm in O, applicable to A–O.
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Neurodegenerative diseases are characterized by a
selective degeneration of speciﬁc neuronal populations.Identiﬁcation of mechanisms of vulnerability and
resistance among neurons with similar properties that
respond diﬀerentially to disease-inducing mutations could
lead to future therapies. Motor neurons that innervate
Fig. 7. Peripherin and dynein show predominant expression in vulnerable hypoglossal and spinal motor neurons in human patient tissues.
Peripherin was preferential to hypoglossal and spinal motor neurons compared to oculomotor motor neurons in non-demented control patients (A–
D, P< 0.0001, n= 3, ANOVA). Peripherin remained restricted to spinal and hypoglossal motor neurons in end-stage ALS patient tissues (E–H,
P< 0.0001, n= 3, ANOVA). Dynein was also preferential to spinal and hypoglossal motor neurons in control patient tissues (I–L, P< 0.0001,
n= 3, ANOVA), while in ALS patients the levels were comparable in all motor neurons groups (M–P, P= 0.7046, n= 4, ANOVA). Scale
bar = 20 lm in O, applies to A–O.
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However, oculomotor motor neurons that regulate eye
movement are for unknown reasons resistant to
degeneration. In this report we have identiﬁed a protein
signature for oculomotor motor neurons in health and in
ALS with the aim of understanding motor neuron
resistance.
We initially considered Gucy1a3 to be a potential
candidate for explaining motor neuron resistance, as it
is preferential to oculomotor motor neurons in wild-type
rats (Hedlund et al., 2010) and mice. Gucy1a3 could limit
unbound NO in the cell and consequently lower levels of
Fas activation, which is detrimental to the cells (Hedlund
et al., 2010). However, Gucy1a3 was evenly distributed
between resistant oculomotor and vulnerable hypoglossal
and spinal motor neurons in symptomatic SOD1G93A mice
and ALS patients, thus rendering it an unlikely candidate
to explain oculomotor resistance.
Parvalbumin has been implicated in oculomotor motor
neuron resistance and its over-expression can increase
the resistance of motor neurons to Ca2+-currents,induced through nerve injury (Dekkers et al., 2004) or
excitotoxic challenge (Van Den Bosch et al., 2002). How-
ever, several of our ﬁndings argue against parvalbumin
being a major factor in oculomotor resistance. As shown
here, resistant oculomotor and vulnerable spinal motor
neurons contained relatively similar levels of parvalbumin
in both mouse and man. Furthermore, in symptomatic
SOD1G93A mice, parvalbumin levels dropped signiﬁcantly
in oculomotor motor neurons, while remaining unchanged
in spinal motor neurons. Finally, we could show that levels
of parvalbumin diﬀered greatly between individual motor
neurons, with some oculomotor motor neurons lacking
parvalbumin in both health and ALS despite their resistant
phenotype.
Inhibitory synaptic transmission, mediated by GABA
and glycine neurotransmission, appears to diﬀer
between oculomotor and hypoglossal motor neurons
and may in part underlie their diﬀerential vulnerability
(Lorenzo et al., 2006). Our study of Gabra1 and Gabra2
expression complements previous analyses in control ani-
mals (Lorenzo et al., 2006; Brockington et al., 2013) and
228 L. Comley et al. / Neuroscience 291 (2015) 216–229control patients (Brockington et al., 2013), showing that
Gabra1 was preferentially present in oculomotor motor
neurons. In addition we also show that Gabra1 remains
preferential to oculomotor motor neurons in symptomatic
SOD1G93A mice and in end-stage ALS patients. This
could indicate Gabra1 as a candidate for oculomotor
resistance. Conversely, Gabra2 was preferential to spinal
motor neurons in man and mouse in health and in ALS.
However, the relative diﬀerence in Gabra2 levels between
oculomotor and spinal motor neurons in man appeared
smaller in ALS patient motor neurons (1.3-fold) than in
control patients (1.6-fold). This could either indicate a
regulation of Gabra2 levels or loss of spinal motor neu-
rons with higher levels of Gabra2. Finally, our data on
Gabra1 and Gabra2 indicate that diﬀerences in inhibitory
synaptic transmission between resistant oculomotor and
vulnerable motor neurons are largely maintained even at
end-stage of disease.
From our ﬁndings it appears that oculomotor motor
neurons in mouse and man have lower levels of the
motor protein dynein and the intermediate neuroﬁlament
peripherin. This might simply reﬂect a lesser need for
retrograde transport due to a smaller cell body size,
shorter axon and lower energy dependence.
Additionally, it might render oculomotor motor neurons
less vulnerable to changes in retrograde transport,
which are known to occur in ALS (Collard et al., 1995)
and which we indirectly document here. Indeed, dys-
regulation in either the dynein–dynactin complex
(LaMonte et al., 2002; Hafezparast et al., 2003) or periph-
erin (Beaulieu et al., 1999) causes spinal motor neuron
degeneration in mice, presumably through defective
axonal transport (LaMonte et al., 2002; Hafezparast
et al., 2003; Millecamps et al., 2006). Furthermore, sALS
patient spinal motor neurons show decreased levels of
dynactin (Jiang et al., 2007). Our human tissue analyses
showed that dynein was preferential to hypoglossal and
spinal motor neurons in control patient tissues, while in
ALS patients dynein was present at similar levels in all
motor neuron groups. These data could either reﬂect a
decrease of dynein in vulnerable motor neurons or a loss
of the motor neurons that expressed high levels of dynein
to begin with. Based on these data it is compelling to infer
that motor neurons that are less dependent on retrograde
transport normally might do better in disease when there
is a dramatic decrease in dynein, as seen here in the
SOD1G93A mouse. However, impaired dynein function
actually appears beneﬁcial in the mutant SOD1 fALS mice
(Kieran et al., 2005). This indicates that the decrease in
dynein within SOD1G93A motor neurons during disease
progression could in part be beneﬁcial and reﬂect a pro-
tective need to decrease axonal transport, but this
remains to be addressed. Peripherin, on the other hand,
remained preferential to motor neurons in the spinal cord
also in ALS patient tissue. However, our data indicate that
normal physiological diﬀerences in peripherin levels per
se are not necessarily a factor of vulnerability. In fact,
the increase in peripherin levels in spinal motor neurons
in the SOD1G93A mice and the persistence of peripherin
in spinal motor neurons remaining in end-stage patients
could instead reﬂect regenerative responses indegenerating axons. Such a regenerative response is
indicated through the presence of peripherin+ ChAT-
negative neurons in the CNXII and spinal cord in
SOD1G93A mice, and will be subjected to further
investigation.CONCLUSION
We have identiﬁed a protein signature for oculomotor
motor neurons in health and in ALS, which could in
part explain their preservation in disease both in man
and mouse. The relative conservation of signals
across species infers that transgenic SOD1G93A mice
could be used to predict mechanisms of motor neuron
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